Evidence map›Paper›PMID 34858480›Full record

ArticleFrontiers in genetics2021

Evolutionary and Antigenic Profiling of the Tendentious D614G Mutation of SARS-CoV-2 in Gujarat, India.

Jay Nimavat, Chandrashekar Mootapally, Neelam M Nathani, Devyani Dave, Mukesh N Kher, Mayur S Mahajan, Chaitanya G Joshi, Vaibhav D Bhatt

Abstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jay NimavatDepartment of Pharmaceutical Sciences, Saurashtra University, Rajkot, India.
Chandrashekar MootapallySchool of Applied Sciences and Technology (GTU-SAST), Gujarat Technological University, Ahmedabad, India.
Neelam M NathaniSchool of Applied Sciences and Technology (GTU-SAST), Gujarat Technological University, Ahmedabad, India.
Devyani DaveDepartment of Pharmaceutical Sciences, Saurashtra University, Rajkot, India.
Mukesh N KherL. M. College of Pharmacy, Ahmedabad, India.
Mayur S MahajanAtal Incubation Centre, Gujarat Technological University, Ahmedabad, India.
Chaitanya G JoshiGujarat Biotechnology Research Centre, Department of Science and Technology, Gandhinagar, India.
Vaibhav D BhattSchool of Applied Sciences and Technology (GTU-SAST), Gujarat Technological University, Ahmedabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humankind has suffered many pandemics in history including measles, SARS, MERS, Ebola, and recently the novel Coronavirus disease caused by SARS-CoV-2. As of September 2021, it has affected over 200 million people and caused over 4 million deaths. India is the second most affected country in the world. Up to this date, more than 38 Lakh viral genomes have been submitted to public repositories like GISAID and NCBI to analyze the virus phylogeny and mutations. Here, we analyzed 2349 genome sequences of SARS-CoV-2 submitted in GISAID by a single institute pertaining to infections from the Gujarat state to know their variants and phylogenetic distributions with a major focus on the spike protein. More than 93% of the genomes had one or more mutations in the spike glycoprotein. The D614G variant in spike protein is reported to have a very high frequency of >95% globally followed by the L452R and P681R, thus getting significant attention. The antigenic propensity of a small peptide of 29 residues from 597 to 625 of the spike protein variants having D614 and G614 showed that G614 has a little higher antigenic propensity. Thus, the D614G is the cause for higher viral antigenicity, however, it has not been reported to be effective to be causing more deaths.

Indexed as

antigenic propensitycladesD614GSARS-CoV-2spike glycoprotein

Identifiers

PMID34858480
PMCPMC8632030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.